Team

FSD Pharma was founded by Thomas Fairfull (retired), Zeeshan Saeed and Anthony Durkacz. The first initial of the last names of each of the founders represent the letters FSD.

Our leadership consists of a passionate management team with diverse industry knowledge, committed to science, therapeutic drug discovery and development.

With a highly-accomplished Board of Directors and BioSciences team, we have the adequate depth and breadth required to pursue our strategic vision.

Board of Directors

Anthony Durkacz

Founder, Interim CEO & Executive Co-Chairman of the Board

Mr. Durkacz is the "D" in FSD. Mr. Durkacz has served as a director and the Executive Vice-President of First Republic Capital Corporation since 2014. Prior to co-founding the Company, Mr. Durkacz was President of Capital Ideas Investor Relations.

Learn More »

Zeeshan Saeed

Founder, President & Executive Co-Chairman of the Board

Mr. Saeed is the "S" in FSD. Mr. Saeed started as a partner in FSD when it was just a business plan on paper. He was instrumental in raising the initial seed capital and assisted FSD’s transition into a public company. He played a key role in bringing together a team of professionals to facilitate crucial relationships and develop the Company’s business plan.

Learn More »

Donal Carroll

Director

Donal Carroll joined FSD Pharma as interim Chief Financial Officer in 2018 and was appointed to the position on a permanent basis in December 2019. An experienced business executive, Mr. Carroll has 20 years of corporate finance leadership and public company experience, as well as deep expertise in syndicate investing both in equity and debt securities.

Learn More »

Lawrence (Larry) Latowsky

Director

Mr. Latowsky is currently Chief Executive Officer of Canntab Therapeutics Ltd., an innovator in cannabinoid and terpene blends in hard pill form for therapeutic application. Mr. Latowsky has held a number of leadership positions throughout his career, including Chairman and Chief Executive Officer of Top Drug Corp.

Learn More »

Adnan Bashir

Director

Mr. Bashir is one of the first investors of FSD Pharma. He brings a wealth of over 14 years of experience in strategic management and operations. In the last decade, Mr. Bashir was General Manager for Al Batha group, a diversified business conglomerate based in Dubai, UAE. Mr. Bashir was responsible for overseeing the management and operations of 4 companies within the group and was instrumental in acquiring and developing new businesses and partners from Europe, the US and China

Learn More »

Fernando Cugliari

Director

Mr. Cugliari has over 20 years of experience in finance and law, and is an attorney qualified to practice in Ontario and the Cayman Islands. Mr. Cugliari is currently an International Investment Advisor at CIBC FirstCaribbean International Bank, where he provides comprehensive investment advisory services to high and ultra-high-net-worth individuals and their families, as well as insurance, corporate, institutional and pension fund clients.

Learn More »

Nitin Kaushal

Director

Since March 2020, Nitin Kaushal has served as President of Anik Capital Corp., his family's holding company. In February 2020, he retired from PricewaterhouseCoopers Canada ("PwC") where he was a Managing Director in the corporate finance practice, which focused on the pharmaceutical and healthcare spaces.

Learn More »

Management Team

Dr. Lakshmi P. Kotra, PhD

CEO of Lucid

Dr. Lakshmi Kotra, Senior Scientist at Krembil Brain Institute, University Health Network (UHN), and Professor of Medicinal Chemistry at the University of Toronto, joined FSD Pharma as CEO of its wholly-owned subsidiary, Lucid, upon completion of its acquisition of Lucid Psycheceuticals in September 2021....

Learn More »

Nathan Coyle, CPA

Chief Financial Officer

Nathan Coyle joined FSD Pharma Inc in 2020 as Corporate Controller and was appointed to the Interim Chief Financial Officer role in 2021. Mr. Coyle has 15 years of executive business experience as a finance leader in both public and private roles. With a keen eye for analytical analysis and innovative ideas he has always led his team to success.

Learn More »

Zachary Dutton

Co-Founder of Prismic Pharmaceuticals

Zachary Dutton joined FSD Pharma in July 2019 following the acquisition of Prismic Pharmaceuticals, where he was its CEO.   Mr. Dutton is a multifunctional healthcare professional and leader with over 20 years business and entrepreneurial experience with a focus on corporate development, partnerships and strategic planning.  He has broad experience within healthcare and has held senior positions in multiple sectors including prescription drugs, medical foods and dietary supplements.

Learn More »

Sara May, PhD

Senior Vice-President

Dr. Sara May is a Ph.D. graduate with a multidisciplinary background in plant breeding and crop genetics with over ten years’ experience designing, implementing and managing large-scale projects in the field, lab and greenhouse. She is the former President of FV Pharma, Inc., and has extensive work experience with all aspects of National, International, Provincial and Regional Legislative Acts and Regulations. Dr. May has deep domain expertise in the Medical Cannabis industry, which includes managing large scale operations, developing and implementing quality control and quality assurance methods and standard operating procedures and HACCP.

Learn More »

Scientific Advisory Board

Albert H.C. Wong, MD, PhD, FRCP(C)

Expert Advisory Committee Member

Dr. Albert Wong, Professor of Psychiatry, University of Toronto, and a Research Scientist in the Neuroscience Department and Staff Psychiatrist in the Schizophrenia Division at the Centre for Addiction and Mental Health, is a world-renowned expert on schizophrenia. His research focusses on the investigation of genetic, cellular and developmental mechanisms underlying psychiatric symptoms.

Learn More »

Peter K. Stys, MD, FRCP(C), FRSC

Expert Advisory Committee Member

Dr. Peter Stys, Professor of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, is a neurologist/neuroscientist and a world leader in the detailed study of pathophysiological mechanisms of white matter injury in stroke and trauma.

Learn More »

Shannon Dunn, PhD

Expert Advisory Committee Member

Dr. Shannon Dunn, a scientist at the University Health Network and Women’s College Hospital, and an Associate Professor in the Department of Immunology at the University of Toronto, currently leads a research program focused on various risk factors for the development of T cell-mediated autoimmune diseases, such as multiple sclerosis....

Learn More »

Hance Clarke, MD, FRCPC

Expert Advisory Committee Member

Dr. Hance Clarke is a staff anesthesiologist and the Director of Pain Services at the Pain Research Unit at the Toronto General Hospital (TGH). He is currently the knowledge Translation Chair for the University of Toronto Centre for the Study of Pain, and in 2016, was awarded an early Career Award from the Canadian Pain Society.

Learn More »